In breast cancer, Song et al. found that knocking down the expression of SORBS1 promotes the EMT process and reduces the sensitivity to chemicals, especially cisplatin, by inhibiting p53 in BRCA cells [73]. Here, SORBS1 is linked to breast cancer.